Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) Context:
TransCon Growth Hormone (
GH) (Ascendis Pharma) is a long-acting recombinant sustained
Maniatis, AK;,
Casella, SJ;,
Nadgir, UM;,
Hofman, PL;,
Saenger, P;,
Chertock, ED;,
Aghajanova, EM;,
Korpal-Szczyrska, M;,
Vlachopapadopoulou, E;,
Malievskiy, O;,
Chaychenko, T;,
Cappa, M;,
Song, WJ;,
Mao, M;,
Mygind, PH;,
Smith, AR;,
Chessler, S;,
Komirenko, AS;,
Beckert, M;,
Aimee, D Shu,
Paul, S Thornton (2022) with lonapegsomatropin. Subjects in the United States switched to the
TransCon hGH Auto-Injector when available
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) doses, compared with daily recombinant human
GH (r-
hGH).
Setting: The trial was conducted in 14
Alkylation of dimethyl 2-bromo-1
H-imidazole-4,5-dicarboxylate with 2-chloromethylthiirane gave